Key Takeaways
- • Clinical ink, a global clinical trial technology company, has announced new investments from Ardan Equity, a private equity firm specializing in healthcare technology, made through Ardan Equity Fund I.
- • GI Partners, which has partnered with Clinical ink since 2020, participated through GI Partners Fund VI, with existing investors also taking part in the round.
- • The deal is one of several items in AltAssets' Deal Roundup, which also reports Delegance Brokerage raising $3.1 million in a pre-seed round.
- • Available source text is limited to the publisher summary and an opening paragraph; the full deal value for the Clinical ink transaction was not disclosed in the material reviewed.
Summary
Clinical ink, a global clinical trial technology company, has announced investments from Ardan Equity, a private equity firm focused on healthcare technology, according to AltAssets Private Equity News. The investment was made through Ardan Equity Fund I.
GI Partners, a private investment firm that has partnered with Clinical ink since 2020, also invested through GI Partners Fund VI. Existing investors, including GI Partners funds, participated in the transaction alongside the new investment from Ardan.
The announcement is featured in AltAssets' Deal Roundup, which also covers Delegance Brokerage's $3.1 million pre-seed round. The available source material does not disclose the total size of the Clinical ink investment or its valuation, and the full article is restricted to premium subscribers.
GI Partners, a private investment firm that has partnered with Clinical ink since 2020, also invested through GI Partners Fund VI. Existing investors, including GI Partners funds, participated in the transaction alongside the new investment from Ardan.
The announcement is featured in AltAssets' Deal Roundup, which also covers Delegance Brokerage's $3.1 million pre-seed round. The available source material does not disclose the total size of the Clinical ink investment or its valuation, and the full article is restricted to premium subscribers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.